JGC
BTAI icon

J. Goldman & Co’s BioXcel Therapeutics BTAI Stock Holding History

J. Goldman & Co’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,581
Closed -$1.17M – 442
2020
Q4 		$1.17M Sell
1,581
-1,094
-41% -$852K 0.06% 226
2020
Q3 		$1.86M Buy
+2,675
New +$2.01M 0.13% 175

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

J. Goldman & Co's BTAI Position: Q1 2021 in Review

J. Goldman & Co sold out of BioXcel Therapeutics (BTAI) in Q1 2021, closing a stake of 1,581 shares — an estimated $1.17M sold.

J. Goldman & Co first reported a position in BTAI in Q3 2020 and held it in 2 quarters. The position peaked at $1.86M in Q3 2020. 116 funds tracked by Wall St. Rank hold BTAI as of Q1 2021.

  • J. Goldman & Co reported no remaining BioXcel Therapeutics position as of Q1 2021 after selling out during the quarter.
  • J. Goldman & Co sold 1,581 BioXcel Therapeutics shares in Q1 2021, an estimated $1.17M.
  • J. Goldman & Co first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 2 quarters.
  • J. Goldman & Co's BioXcel Therapeutics position peaked at $1.86M in Q3 2020.
  • 116 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2021.

Based on J. Goldman & Co's 13F filing for Q1 2021, filed 17 May 2021.